Zoledronic acid in the management of metastatic bone disease
- 22 November 2006
- journal article
- review article
- Published by Informa UK Limited in Expert Opinion on Biological Therapy
- Vol. 6 (12), 1333-1348
- https://doi.org/10.1517/14712598.6.12.1333
Abstract
Bisphosphonate therapy has become a standard of therapy for patients with malignant bone disease. Moreover, in vivo preclinical and preliminary clinical data suggest that bisphosphonates may prevent cancer treatment-induced bone loss and the onset of malignant bone disease in patients with early-stage cancer. This comprehensive review critically reports the several preclinical evidences of action of bisphosphonates on osteoclasts, lymphocytes and tumour cells. In addition, all the clinical trials evaluating the effects of principal bisphosphonates on skeletal disease progression in patients with breast cancer, prostate cancer, non-small cell lung cancer and other cancers have been reported. Of the available bisphosphonates, intravenous zoledronic acid has demonstrated the broadest clinical activity and is actually approved for the treatment of bone metastases from any solid tumour in many countries. Renal safety is an important consideration for oncologists who are treating patients with bisphosphonates. This issue and the other topics relating to the safety of bisphosphonates are discussed in this review.Keywords
This publication has 97 references indexed in Scilit:
- Ibandronate: Its Role in Metastatic Breast CancerThe Oncologist, 2006
- Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's DiseaseNew England Journal of Medicine, 2005
- Osteonecrosis of the Jaw and BisphosphonatesNew England Journal of Medicine, 2005
- Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfectaBone, 2004
- Hematologic malignancies: New developments and future treatmentsSeminars in Oncology, 2002
- Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing BisphosphonatesBiochemical and Biophysical Research Communications, 1999
- Comparative Tolerability of Drug Therapies for Hypercalcaemia of MalignancyDrug Safety, 1999
- Sentinel function of broadly reactive human γδ T cellsImmunology Today, 1997
- BisphosphonatesDrugs, 1991
- Cox's Regression Model for Counting Processes: A Large Sample StudyThe Annals of Statistics, 1982